Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Proglumide”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources
PubMed1994

[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].

This study was designed to determine whether or not chemo-endocrine therapy after the resection of liver metastasis from colorectal cancer would prevent re-recurrence in the liver. Postoperatively, seven patients received proglumide gastrin antagonist (1,200 mg/day) +5'-DFUR (800 mg/day) orally for 2 years. MMC 6-10 mg and ADR 20 mg were infused every two weeks alternately for 1 year via catheter in the common hepatic artery. After median follow-up of 39 months, re-recurrence rate in the remnant liver after hepatic resection was 14% (1/7) for patients with chemo-endocrine therapy and 52% (24/46) for the controls. These results suggest the possibility that chemo-endocrine therapy is effective to prevent re-recurrence of liver metastasis in patients with colorectal cancer.

Administration, Oral↗
PubMedDate not supplied

[Antigastrin therapy in gastric ulcer].

A brief review of the role of gastrin on gastric secretion and its influence in the genesis of peptic ulcer is made. A report is made of the pharmacological studies of Proglumida and its antigastrin action and the interest its association with Hioscin Butil-Bromuro may represent in the antiulcer therapy. A study is made of 26 patients submitted to a general treatment for peptic ulcer this drug together with a bland diet and psychotherapy. The results were: 19 (73%) cases cured; 6 (23%) cases improved; no results in 1 (4%) case. No secondary side effects appear and the symptomatic response appears 8 days after the treatment is initiated. The dosis used is of 2 tablets before the 3 main meals. Each tablet contains 250 mg of Proglumide and 10 mg of Hioscin Butil-Bromuro. It is considered useful in the antiulcer therapy to have available a drug which can control the physiological effects of gastrin and from this point of view its action is different from that of the antiacids and anticolinergics.

Adult↗
PubMed1995

Ca2+ antagonists reveal a novel inhibitory effect of caerulein on guinea pig ileum.

The peptide caerulein (CK) is a potent muscle stimulant of guinea pig ileum and its effect is Ca2+-dependent. Ca2+ antagonist drugs administered to the organ perfusion solution diminished the twitches of the electrically stimulated ileum. Subsequent administration of caerulein reinforced this inhibition of contraction and acetylcholine (ACh) release by the ileum. This effect was antagonized by cholecystokinin antagonists (i.e., proglumide and loxiglumide) and by dibutyryl-cyclic-guanosine monophosphate, which overcame the stimulant effect of the peptide. These findings indicated that in the guinea pig ileum, caerulein exerts two opposite effects, both of which are mediated by the same receptor: a stimulation effect, with an increase in acetylcholine release when the organ is incubated in normal saline, and a relaxation effect, with a reduction in acetylcholine release when the ileum is bathed with calcium antagonist drugs.

Acetylcholine↗
PubMed1998

[Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis].

The aim of this study was to determine whether chemo-endocrine therapy after the resection of liver metastasis from colorectal cancer would prevent recurrence in the remnant liver and prolong survival. Eleven colorectal cancer patients underwent hepatic resection for liver metastasis. Subsequently, they were administered Proglumide gastrin antagonist 1,200 mg/day + 5'-DFUR 800 mg/day for 2 years. In seven of them, MMC 6-10 mg and ADM 20 mg were infused intra-arterially every two weeks alternately for one year. In four of them, 5-FU 250 mg/day was infused for seven days continuously intra-arterially every two weeks for one year. Recurrence in the remnant liver occurred in four of 11 patients. All of these patients underwent repeated hepatectomy. The mean disease-free survival in the remnant liver was 37 months and the five-year survival rate was 91%. These results indicate that intra-arterial chemotherapy with gastrin receptor antagonist might be effective for adjuvant therapy in patients with resectable liver metastasis from colorectal cancer.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1998

Cholecystokinin stimulates ascorbic acid secretion through its specific receptor in the perfused stomach of rats.

We have previously demonstrated that endogenous ascorbic acid is secreted into the gastric lumen by cholinergic stimulation in both conscious pylorus-ligated rats and the perfused stomach of unconscious rats, and that gastrin, a potent gastric stimulatory peptide hormone, has no effect. In the present study, the effects of some gastrointestinal peptide hormones on gastric ascorbic acid secretion were further examined in the perfused stomach of rats. An intravenous administration of cholecystokinin octapeptide (CCK-8) significantly increased gastric ascorbic acid secretion at a dose of 1.0 and 4.0 micrograms/kg, whereas the other three peptides examined, bombesin, neurotensin and substance P, showed no or little effect at the doses which were quite commonly employed for evaluation of various gastric functions. CCK-8-induced ascorbic acid secretion was reduced by pretreatment with proglumide, which is a CCK receptor antagonist, but not by pretreatment with atropine. These results indicate that gastric ascorbic acid secretion is physiologically regulated not only by muscarinic receptor-associated cholinergic stimulation but also by CCK receptor-associated humoral stimulation.

Animals↗
PubMed2004

Glycine-extended gastrin induces matrix metalloproteinase-1- and -3-mediated invasion of human colon cancer cells through type I collagen gel and Matrigel.

The effects of glycine-extended gastrin (G-Gly) on the invasion by colon cancer cells through stromal extracellular matrix and the role of metalloproteinases (MMPs) in this invasion were investigated. We found that 10(-9)-10(-6) M G-Gly significantly increased the invasiveness of 2 human colon cancer cell lines, LoVo and HT-29, both expressing the G-Gly-specific binding site but little gastrin/CCK-B receptor (gastrin receptor). LoVo cells expressed MMP-1, -2, -3 and -9. An amount of 10(-7) M G-Gly enhanced collagenase MMP-1 expression. Overexpression of enhanced green fluorescent protein (EGFP)-fused MMP-1 in LoVo cells, by cDNA transfection, enhanced invasiveness through type I collagen gel. Immunofluorescence study revealed that G-Gly increased the number of cytoplasmic vesicles containing MMP-1, some vesicles being released from the cells. The MMP-1 vesicles contained one of the ubiquitous coat proteins, Golgi-localized, gamma-adaptin ear-containing, ARF-binding proteins-2 (GGA-2). MMP-1 also colocalized with CD147 (EMMPRIN, an extracellular matrix metalloproteinase inducer in adjacent stromal cells). It was suggested that G-Gly increased the number of vesicles containing MMP-1 and that MMP-1 interacted with CD147 to increase invasion. G-Gly significantly enhanced the production of MMP-3, an activator of MMP-1 and -9, as well as gelatinase MMP-9 activity. The G-Gly-mediated MMP-9 increase was inhibited by treatment with anti-MMP-3 IgG and MMP-3 siRNA. Furthermore, G-Gly increased the proMMP-2 level, although no activated MMP-2 was found in conditioned medium in either the presence or the absence of G-Gly. By contrast, gastrin (10(-7) M) had no effect on the levels of these MMPs or the invasiveness of colon cancer cells in type I collagen gel and Matrigel. These effects of G-Gly on the activity and expression of MMPs and the invasiveness of colon cancer cells were inhibited by treating the cells with a broad-spectrum metalloproteinase inhibitor (CGS27023A) and nonselective gastrin/CCK receptor antagonists (proglumide and benzotript). But a gastrin/CCK-B receptor antagonist (YM022) did not inhibit the increased invasion by G-Gly. Together, these results demonstrate that G-Gly renders colon cancer cells more invasive by increasing MMP-1 and MMP-3 expressions via the putative G-Gly receptor and would thus be a good molecular target in a clinical setting.

Biocompatible Materials↗
PubMed2005

Cholecystokinin inhibits evoked inhibitory postsynaptic currents in the rat nucleus accumbens indirectly through gamma-aminobutyric acid and gamma-aminobutyric acid type B receptors.

We recently reported that cholecystokinin (CCK) excited nucleus accumbens (NAc) cells and depressed excitatory synaptic transmission indirectly through gamma-aminobutyric acid (GABA), acting on presynaptic GABAB receptors (Kombian et al. [2004] J. Physiol. 555:71-84). The present study tested the hypothesis that CCK modulates inhibitory synaptic transmission in the NAc. Using in vitro forebrain slices containing the NAc and whole-cell patch recording, we examined the effects of CCK on evoked inhibitory postsynaptic currents (IPSCs) recorded at a holding potential of -80 mV throughout CCK-8S caused a reversible inward current accompanied by a concentration-dependent decrease in evoked IPSC amplitude. Maximum IPSC depression was approximately 25% at 10 microM, with an estimated EC50 of 0.1 microM. At 1 microM, CCK-8S induced an inward current of 28.3 +/- 4.8 pA (n=6) accompanied by an IPSC depression of -18.8% +/- 1.6% (n=6). This CCK-induced IPSC depression was blocked by pretreatment with proglumide (100 microM; -3.7% +/- 6.9%; n=4) and by LY225910 (100 nM), a selective CCKB receptor antagonist (4.4% +/- 2.6%; n=4). It was not blocked by SCH23390 (10 microM; -23.5% +/- 1.3%; P < 0.05; n=7) or sulpiride (10 microM; -21.8% +/- 5.1%; P <0.05; n=4), dopamine receptor antagonists. By contrast, it was blocked by CGP55845 (1 microM; -0.4% +/- 3.4%; n=5) a potent GABAB receptor antagonist, and by forskolin (50 microM; 9.9% +/- 5.2%; n=4), an adenylyl cyclase activator, and H-89 (1 microM; 6.9% +/- 3.9%; n=4), a protein kinase A (PKA) inhibitor. These results indicate that CCK acts on CCKB receptors to increase extracellular levels of GABA, which then acts on GABAB receptors to decrease IPSC amplitude.

Adenylyl Cyclases↗
PubMed1991

Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons.

Extracellular recording techniques were combined with antidromic stimulation to examine the effects of C-terminal cholecystokinin (CCK) fragments and CCK antagonists on the activity of identified mesoaccumbens dopamine (MADA) neurons in chloral hydrate-anesthetized rats. These experiments were designed to determine the receptor selectivity of sulfated CCK octapeptide (CCK-8S) effects on MADA cells. Neither CCK tetrapeptide (CCK-4) nor unsulfated CCK octapeptide (CCK-8U) significantly altered MADA cell basal firing rate or responsiveness to the inhibitory effects of the D2 DA agonist quinpirole. As reported previously for ventral tegmental area DA cells, CCK-8S produced increases or decreases in the firing rate of most MADA cells sampled. CCK-8S also enhanced the sensitivity of MADA neurons to quinpirole-induced inhibition. This increase in sensitivity to quinpirole was blocked by pretreatment with the nonselective CCK receptor antagonist proglumide and the preferential CCK-A receptor antagonist CR 1409 but not by the preferential CCK-B receptor antagonist L-365,260. The inactivity of CCK-4 and CCK-8U in these tests and the results with the antagonists suggest that the effects of CCK-8S on MADA neuronal activity are mediated by CCK-A receptors.

Animals↗
PubMed1995

Investigation into the role of cholecystokinin (CCK) in the induction and maintenance of maternal behavior in rats.

The biochemical regulation of maternal behavior has been extensively studied. Cholecystokinin (CCK), a gut peptide that is also present in the brain, recently has been implicated in the onset of maternal behavior in estrogen-primed virgin rats. The objective of the present set of studies was to delineate the role of CCK in the onset (Experiments 1-3) and maintenance (Experiments 4 and 5) of maternal behavior in rats. In the first study intracerebroventricular (i.c.v.) administration of CCK was unable to stimulate the onset of maternal behavior in estrogen-primed virgin rats. Similarly, i.c.v. infusions of CCK into pregnant rats, starting on Day 17 of gestation (Experiment 2), did not advance the onset of maternal behavior. Moreover, when CCK-filled minipumps were implanted intraperitoneally in estrogen-primed virgin rats, the rate of onset of maternal behavior was unaffected (Experiment 3). In contrast, direct infusions of CCK into the MPOA blocked the disruptive effects of beta-endorphin on the maintenance of maternal behavior in postpartum lactating rats (Experiment 4). In addition, proglumide, a CCK receptor antagonist, disrupted maternal behavior in postpartum lactating rats by increasing latencies to retrieve and crouch over the young (Experiment 5). These results support an involvement of CCK in the maintenance, but not the onset, of maternal behavior in rats.

Animals↗
PubMed1989

Effects of synthetic human gastrin-releasing peptide on pancreatic exocrine secretion and release of pancreatic polypeptide in conscious rats.

The effects of a newly synthesized peptide, human gastrin-releasing peptide (hGRP), on the pancreatic exocrine secretion and the release of pancreatic polypeptide (PP) were examined in the conscious rat. Plasma PP concentrations were determined by a recently established specific radioimmunoassay for rat PP. Amounts of 0.18, 0.35, and 3.5 nmol/kg/h hGRP significantly stimulated both pancreatic exocrine secretion and 0.35 nmol/kg/h of hGRP increased PP release. Simultaneously infused proglumide (300 mg/kg/h) did not affect either pancreatic exocrine secretion or PP release. However, simultaneous infusion of atropine (100 micrograms/kg/h) slightly inhibited PP release, but did not restrict the incremental response of pancreatic protein secretion to hGRP. These results suggest that hGRP directly stimulates pancreatic exocrine secretion and PP release.

Animals↗
PubMed1986

In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.

In vivo electrochemical techniques were used to study the effects of the sulfated (CCK8-S) and unsulfated (CCK8-US) forms of the cholecystokinin octapeptide on dopamine (DA) release in the nucleus accumbens. A dose-dependent inhibition of DA release was observed only with CCK8-S. This inhibitory effect was blocked by the CCK receptor antagonist proglumide, and was reversed by systemic injections of apomorphine. Given that apomorphine can hyperpolarize DA neurons, these data indicate that CCK may inhibit the release of DA by a process of depolarization block and suggest a mechanism by which CCK may regulate overactive mesolimbic DA transmission.

Animals↗
PubMed1982

High-affinity binding sites for gastrin on isolated rabbit gastric mucosal cells.

A biologically active gastrin analogue, [125I](Nle11)-HG-13, appears to bind specifically to saturable binding sites on isolated rabbit gastric mucosal cells: Kd = 70 pM at pH 7.4 and at 37 degrees C. Increasing incubation temperature from +4 degrees C to +37 degrees C increased specific binding. Gastrin binding was shown to be reversible and the dissociation rate was enhanced with cold gastrin. The binding sites were saturated with 0.2 fmol of labelled gastrin per 10(6) mucosal cells. Gastrin binding was not inhibited by secretin, glucagon, Met-enkephalin, physalaemin, eledoisin, BPP, VIP, carbachol, histamine, atropine or cimetidine. Gastrin analogues (HG-4, HG-8, (Leu15)-HG-17), CCK-7 and gastrin antagonists (proglumide or benzotript) inhibited [125I](Nle11)-HG-13 specific binding. We concluded that isolated cells from rabbit gastric fundic mucosa contain high-affinity binding sites for a gastrin analogue (Nle11)-HG-13.

Animals↗
PubMed1991

Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat.

Peripheral administration of cholecystokinin tetrapeptide (CCK-4) at non-sedative doses (25-50 micrograms/kg) decreased the exploratory activity of rats in an elevated plus-maze. This effect was antagonized by treatment with CCK receptor antagonists proglumide (1 and 10 mg/kg), lorglumide (0.1 and 1 mg/kg), L 365,260 (10 micrograms/kg) and devazepide (1 mg/kg). The results suggest that the exploratory behaviour of rats can be altered by pharmacological manipulations at CCK-B receptors.

Animals↗
PubMed1995

Binding of progastrin fragments to the 78 kDa gastrin-binding protein.

The non-selective gastrin/cholecystokinin receptor antagonists proglumide and benzotript inhibit colon carcinoma cell proliferation by binding to the 78 kDa gastrin-binding protein (GBP) (Baldwin, Proc. Natl. Acad. Sci. USA, 91 (1994) 7593-7597). However, although most colon carcinoma cell lines synthesize progastrin, production of mature amidated gastrin17 has not been observed. In order to define the structural requirements for the binding of gastrin to the GBP the affinities of various fragments of amidated and C-terminally extended gastrin17 for the GBP have been measured. The results indicate that the GBP recognizes both N- and C-termini of gastrin17. Moreover since C-terminal amidation is not a prerequisite for binding of gastrin to the GBP, the GBP is a potential target for the autocrine effects of progastrin.

Amino Acid Sequence↗
PubMed1987

Pharmacologic characterization of excitatory and inhibitory cholecystokinin receptors of the cat gallbladder and sphincter of Oddi.

The pharmacologic properties and specificity of cholecystokinin (CCK) receptors of the biliary tract were investigated by testing various sulfated and desulfated CCK fractions and by using specific CCK-gastrin antagonists. Sulfated CCK-7 (5-80 pmol/kg) caused gallbladder contraction and sphincter of Oddi relaxation. Denervation with tetrodotoxin decreased the gallbladder response by 50% and changed the sphincter of Oddi response from relaxation to contraction. Desulfated CCK-7 (80-400 pmol/kg) caused a weak gallbladder contraction that was unaffected by tetrodotoxin. The gallbladder did not respond to CCK-3 (10-80 nmol/kg) or to CCK-2 (10-160 nmol/kg) in doses that completely relaxed the sphincter of Oddi. These doses, however, were 5-2000 times higher than the maximal dose of sulfated CCK-7. After denervation with tetrodotoxin, desulfated CCK-7 (10-400 pmol/kg) induced a weak sphincter of Oddi contraction even with doses five times greater than the maximal dose of sulfated CCK-7. The denervated sphincter of Oddi did not respond to CCK-3 (10-80 nmol/kg) or CCK-2 (10-160 nmol/kg). Furthermore, a continuous proglumide infusion (5-20 mg/kg X min) and bolus doses of dibutyryl cyclic guanosine monophosphate (250-1000 micrograms/kg) blocked the effect of sulfated CCK-8 on the gallbladder and sphincter of Oddi. Higher doses of these antagonists were needed, however, to block the CCK effect on the sphincter of Oddi than on the gallbladder. In contrast, high doses of desulfated CCK-7 (100 pmol/kg) or CCK-3 (200 nmol/kg) did not antagonize the effect of sulfated CCK-8 (10-80 pmol/kg) on the gallbladder. These findings suggest the existence of three sets of specific CCK receptors with molecular configuration requirements determined by the type of cell where these receptors are located: on the postganglionic cholinergic neurons, on the smooth muscle cells of the gallbladder, and sphincter of Oddi, or on the postganglionic noncholinergic, nonadrenergic inhibitory neurons.

Ampulla of Vater↗
PubMed1987

Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats.

Using a specific radioimmunoassay for cholecystokinin (CCK) we have studied the relation between circulating CCK concentrations and the feedback regulation of pancreatic enzyme secretion in conscious rats. Recirculation of diverted bile-pancreatic juice into the duodenum or intraduodenal perfusion of trypsin during biliary-pancreatic juice diversion produced basal output of amylase and trypsin and low portal CCK levels (less than 10 pmol/L). Biliary-pancreatic juice diversion or inactivation of trypsin caused increased CCK concentrations (peak values 50-100 pmol/L) and enzyme outputs. During biliary-pancreatic juice diversion, infusion of the CCK receptor antagonist proglumide suppressed the enzyme response without altering the increase in CCK. Measurement of portal and peripheral CCK during biliary-pancreatic juice diversion yielded values of 131 +/- 37 and 32 +/- 5 pmol/L, respectively. The peripheral CCK levels corresponded to concentrations achieved during exogenous CCK-8 infusion which resulted in similar enzyme outputs. Gel chromatography of portal plasma during diversion of biliary-pancreatic juice revealed one peak of CCK corresponding to CCK-8, and a larger peak eluted between CCK-33 and CCK-8, probably representing CCK-22. Similar CCK components were found in water extracts of jejunal mucosa, whereas the acetic acid extracts mainly contained CCK-33/39. We conclude that the negative feedback regulation of pancreatic enzyme secretion in rats is mediated by the release of CCK from the intestine and that the major molecular form of CCK in plasma is probably CCK-22.

Amylases↗
PubMed1988

Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas.

Chronic feeding of rats with camostate results in pancreatic hypertrophy or hyperplasia, or both. Previous studies suggest that this effect of camostate occurs via an increase in endogenous cholecystokinin due to an enteral feedback mechanism involving the inhibition of trypsin in the duodenum. Studies employing proglumide, a weak and relatively nonspecific cholecystokinin antagonist, have failed to fully abolish camostate-induced pancreas growth. We examined the effects of L-364,718, a new and highly potent cholecystokinin receptor antagonist, on camostate-induced pancreas growth in rats. The pancreas weights and the concentrations of ribonucleic acid, protein, and chymotrypsinogen in the pancreas of rats treated with camostate alone were significantly elevated over those of controls. These effects of camostate were completely abolished in rats treated with camostate + L-364,718. The pancreas weights and the concentrations of deoxyribonucleic acid and ribonucleic acid in the pancreas of rats treated with L-364,718 alone were significantly lower than values in control rats. These data indicate that camostate-induced pancreas growth in rats appears to be dependent on the actions of endogenous cholecystokinin and that cholecystokinin may play a role in the maintenance of pancreatic growth in normal rats.

Animals↗
PubMed1988

Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

A new antagonist of the peripheral cholecystokinin receptor, L-364,718, was found to block the reductions in food intake and exploratory activity induced by intraperitoneal administration of cholecystokinin octapeptide sulfate. L-364,718 significantly reversed the cholecystokinin-induced reduction in feeding at doses of 10 micrograms/kg - 10 mg/kg i.p. L-364,718 significantly reversed the cholecystokinin-induced reduction in exploratory activity at doses of 500 ng/kg - 10 mg/kg i.p. The time course of antagonist activity of L-364,718 was immediate to 90 minutes after intraperitoneal administration. L-364,718 had no significant effect on food intake or exploratory activity when administered alone, over the dose range of 100 ng/kg-10 mg/kg i.p. This compound appears to be at least one hundred times more potent than proglumide or benzotript as an antagonist of the behavioral effects of peripherally administered cholecystokinin.

Animals↗